NEW MODEL: Jh mouse on B6 background Learn More

Jh (C57BL/6)

Constitutive Knockout

Jh (C57BL/6) mouse model

C57BL/6NTac Background

  • Model #
  • Genotype
  • Nomenclature
  • 17758-F
    ko/ko
    C57BL/6NTac-Igh-Jem1Tac
  • 17758-M
    ko/ko
    C57BL/6NTac-Igh-Jem1Tac
  • B cell deficient mice are useful for basic mechanistic studies of immunologic mechanisms as well as host mice in syngeneic tumor studies using immunogenic test articles.
  • Carries a deletion of the endogenous murine J segments of the Ig heavy chain locus.
  • In homozygotes, all four JH gene segments are absent, resulting in cells that cannot produce a complete, recombined version of the variable region of the heavy chain.
  • B cell development halts at the pro-B cell stage without pre-B cell or mature B cells in the bone marrow. There are significantly fewer B220+ cells in spleen, which are exclusively pro-B cells without IgD. See Phenotypic Data section below.
  • This model is expected to have normal T cell development based on published data from a similar model on the BALB/c background.
  • For use in syngeneic experiments, this model is on the C57BL/6NTac background and will successfully engraft cell lines of C57BL/6 origin.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

C57BL/6NTac Background

Origin:

The Jh (C57BL/6) mouse was developed by Taconic Biosciences. The model was created through CRISPR/Cas9-mediated gene editing to delete the entire Igh-J locus including all four transcripts. Targeting occurred in C57BL/6NTac embryos. The selected G1 founder was screened for off-target effects and the targeted locus was sequenced to confirm targeting specificity. Heterozygous animals were intercrossed to generate homozygous mice. The line is maintained by crossing homozygous mice.
The Jh mouse permits clinically relevant dosing of immunogenic test articles in syngeneic tumor model systems Download the Taconic Biosciences' Infographic:
The Jh mouse permits clinically relevant dosing of immunogenic test articles in syngeneic tumor model systems
See how the Jh mouse can enable syngeneic tumor studies for drugs with immunogenicity problems.

Genetics:

Wild type for Nnt mutation

Color:

Black

Species:

Mouse

Initial Publication:

There is no specific publication describing the generation of these mice, but multiple publications exist demonstrating applications using a similar model on the BALB/c background (Taconic model #1147). See reference list.

Other Publications: Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018 Jan 17;10(424):eaan5488.

Xu C, Zhang Y, Rolfe PA, Hernández VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clin Cancer Res. 2017 Oct 1;23(19):5869-5880.

Smith KM, Rahman RS, Spencer LA. Humoral Immunity Provides Resident Intestinal Eosinophils Access to Luminal Antigen via Eosinophil-Expressed Low-Affinity Fcγ Receptors. J Immunol. 2016 Nov 1;197(9):3716-3724.


Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.

  • Conditions of Use specific to Taconic Transgenic Models™ generated using CRISPR/Cas9
    • This Model was generated using CRISPR/Cas9 technology. Taconic uses CRISPR/Cas9 technology to generate and/or distribute gene-edited models under licenses from The Broad Institute, Inc., the Massachusetts Institute of Technology, the President and Fellows of Harvard College, the University of Iowa Research Foundation and ERS Genomics. View the full list of licensed patents.
    • This Model and biological materials derived from it may only be used for purchasers' internal research purposes in the Field, unless purchaser otherwise has rights from the Broad covering such use. "Field" means use as a research tool for research purposes, and expressly excludes any (a) clinical use, (b) human, veterinary, livestock or agricultural use, or (c) manufacture, distribution, sale, promotion, use or other exploitation as a testing service, therapeutic or diagnostic for humans or animals.
    • The Models and biological materials derived from them will not be sold or used to perform services for third parties (unless purchaser is acting on behalf of a third party to which they have communicated these Conditions of Use and which third party has accepted these Conditions of Use), or otherwise used for commercial purposes.
    • Purchasers will only use the Models and biological materials derived from them in compliance with all applicable laws and regulations, including applicable human health and animal welfare laws and regulations.
    • Each non-profit purchaser agrees that it, and not Taconic's licensors, shall be responsible for any liability, damage, loss or expense arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them , including any breach of the Label License "Conditions of Use for Taconic Transgenic Models" by purchaser.
    • Each for-profit purchaser further agrees that it shall indemnify, defend and hold harmless Taconic's licensors against any liability, damage, loss, or expense (including without limitation reasonable attorneys' fees and expenses) incurred by or imposed upon any of Taconic's licensors in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to purchaser's use of the purchased Models and any biological materials derived from them. Each purchaser acknowledges that the purchased Models and any biological materials derived from them and its use may be the subject of one or more issued patents and/or pending patent applications owned by Taconic's licensors, and the purchase of the Models does not convey a license under any claims in the foregoing patents or patent applications.
    B cell development halts at pro-B cell stage without pre-B cell or mature B cells in the bone marrow and there is no IgD expression
    Figure 1: B cell development halts at pro-B cell stage without pre-B cell or mature B cells in the bone marrow and there is no IgD expression.

    There are significantly fewer B220+ cells in spleen, which are exclusively pro-B cells without IgD
    Figure 2: There are significantly fewer B220+ cells in spleen, which are exclusively pro-B cells without IgD.

    Jh (C57BL/6) - Taconic model #17758. Males at MPF health standard. Data provided by an anonymous biotech company.